The FDA clearance opens the door to the world's largest medical device market. With the cost effectiveness and demonstrated ability of our cardiac monitori...
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the q...
Agilent Technologies Inc. (NYSE: A) announced the latest addition to the Cary 3500 UV-Vis Series with the release of the Agilent Cary 3500 Flexible U...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
ZSFab, Inc., a 3D-printing medical device company, is proud to announce that the ZSFab Cervical Interbody System has been successfully used in its first cl...
he Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®) for u...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the ...
The Patent No. US 11,602,282 B2 describes how the signals recorded from Nox standard respiratory effort bands (RIP) can be used to derive information on in...
LTL’s Reorganization Plan Has Significant Support From Claimants The Plan Includes LTL’s Present Value Commitment of $8.9 Billion Payable...
Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-casp...
The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30...
© 2025 Biopharma Boardroom. All Rights Reserved.
